Taysha Gene Therapies (NASDAQ:TSHA) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $7.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Canaccord Genuity Group restated a buy rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. JMP Securities restated a market outperform rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Needham & Company LLC reiterated a buy rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, April 11th. Piper Sandler started coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 price target for the company. Finally, Chardan Capital upped their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the stock a buy rating in a report on Thursday, March 21st. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has an average rating of Buy and a consensus target price of $6.88.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $2.43 on Tuesday. The stock’s 50-day moving average price is $2.65 and its 200 day moving average price is $2.09. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $454.45 million, a PE ratio of -3.63 and a beta of 0.29. Taysha Gene Therapies has a 52-week low of $0.50 and a 52-week high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The company had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. As a group, equities research analysts forecast that Taysha Gene Therapies will post -0.39 EPS for the current year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in shares of Taysha Gene Therapies by 2,035.0% in the third quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after buying an additional 23,378,974 shares in the last quarter. RA Capital Management L.P. acquired a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $58,373,000. RTW Investments LP purchased a new position in Taysha Gene Therapies during the 3rd quarter valued at about $53,382,000. Vanguard Group Inc. raised its position in Taysha Gene Therapies by 235.2% during the third quarter. Vanguard Group Inc. now owns 5,327,864 shares of the company’s stock worth $16,836,000 after acquiring an additional 3,738,616 shares during the last quarter. Finally, Avoro Capital Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 11.0% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,355,555 shares of the company’s stock valued at $7,709,000 after purchasing an additional 430,555 shares in the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.